Oruka Therapeutics, Inc. Common Stock(ORKA)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$69.98
- 52-Week Range
- $10.77 – $91.00
- YTD
- +147.54%
- IV Rank (30D)
- 6.75
- Straddle Price
- $14.40
- P/C Vol Ratio
- 1.07
- Market Cap
- $4.1B
Fair Value
-3.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 10.01% |
| Volatility Risk Premium | +33.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -20.5% |
| Book / Price | 15.2% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $63.31 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $60.43 |
| Bollinger Width / SMA20 | 38.8% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $3B |
Peers used for multiples: ALKS, AMGN, GILD, REGN, RVMD, TVTX, TWST, VRTX
Blended Fair Value
$67.76
Current Price
$69.89
Deviation
-3.0%
Forward-Return Rank
SHORT
gated
?
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -2.8% | +0.03 | -0.39 | 97.5% | — |
| 42d | -2.3% | +0.51 | -0.39 | 97.5% | — |
| 63d | -4.2% | +0.10 | -0.39 | 97.5% | — |
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon).
For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference.
⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 23.4× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.0× · 6 peers |
| Peer P/B | $81.59 | 24% | median 7.8× · 8 peers |
| Peer P/S | n/a | 0% | median 5.1× · 7 peers |
| Market Anchor (SMA50) | $63.31 | 76% | stability 61% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $4.1B
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and i…
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -7.76% | 2 |
| Feb | -16.17% | 2 |
| Mar | +36.11% | 2 |
| Apr | +23.84% | 2 |
| May | -1.46% | 2 |
| Jun | +8.12% | 2 |
| Jul | +21.56% | 1 |
| Aug | -3.27% | 1 |
| Sep | +10.25% | 2 |
| Oct | +33.22% | 2 |
| Nov | -7.15% | 2 |
| Dec | -4.36% | 2 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $60.73
SMA 50: $63.70
SMA 200: $37.60
Current: $69.89
EMA 12: $63.70
EMA 26: $62.35
MACD: 1.3518 | Signal: 1.2407
BULLISH
ADX (14): 21.69
WEAK TREND
+DI: 28.03
−DI: 12.79
Momentum Oscillators
RSI (14): 62.31
NEUTRAL
Stoch %K: 82.09
Stoch %D: 84.37
Williams %R: -6.87
Volume & Volatility
BB Upper: $68.81
BB Lower: $52.64
OVERBOUGHT
OBV: 22,429,328
Vol SMA 20: 1,238,412
Vol ROC: -36.43%
ATR: $4.26
True Range: $3.41
HV 20: 69.9%
HV 30: 71.5%
HV 60: 73.6%
Data Summary
Data Points: 446
Last Updated: 2026-06-13T13:41:35.937000
Date Range: 2024-09-03T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.
Earnings History
1 of 1 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-04-30 | After-Close | 12.83% | 8.33% | 0.65x | Within |
Options Activity
- IV Rank (30D)
- 6.75
- IV Rank (7D)
- 30.76
- Avg IV
- 96.6%
- Straddle (30D)
- $14.40
- Straddle (7D)
- $5.30
- P/C Volume
- 1.07
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.60
- Correlation (SPY)
- 26.1%
- R²
- 0.07
- Ann. Volatility
- 75.8%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 46,771,675 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
2 filers$1.98M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.44M | 72.77% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $539.55K | 27.23% | 2026-03-31 |
4 filers$5.18M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC Custodian | $3.25M | 62.63% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $971.19K | 18.73% | 2026-03-31 |
| 3 | SIMPLEX TRADING, LLC Custodian | $946.66K | 18.26% | 2026-03-31 |
| 4 | GROUP ONE TRADING LLC Custodian | $19.62K | 0.38% | 2026-03-31 |
Insider Activity
Latest: 2026-06-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | KRISTINE M BALL | Director | Grant (A) | +9,136 opt | — | EDGAR | |
| 2026-06-03 | Christopher Nathan Martin | Director | Grant (A) | +9,136 opt | — | EDGAR | |
| 2026-06-03 | Carl Dambkowski | Director | Grant (A) | +9,136 opt | — | EDGAR | |
| 2026-06-03 | Fairmount Healthcare Fund II L.P. | Director | Grant (A) | +45,680 opt | — | EDGAR | |
| 2026-06-03 | Samarth Kulkarni | Director | Grant (A) | +9,136 opt | — | EDGAR | |
| 2026-05-22 | Carl Dambkowski | Director | Mixed | −42,740 | $39.97 | -$5.70M | EDGAR |
| 2026-05-18 | Arjun Agarwal | Senior Vice President, Finance | Mixed | −2,457 | $45.99 | -$382.2K | EDGAR |
| 2026-05-15 | Joana Goncalves | Chief Medical Officer | Mixed | — | $34.58 | -$381.7K | EDGAR |
| 2026-05-01 | Laura Lee Sandler | Chief Operating Officer | Mixed | — | $35.84 | -$280.4K | EDGAR |
| 2026-04-15 | Joana Goncalves | Chief Medical Officer | Mixed | — | $36.72 | -$411.6K | EDGAR |
| 2026-03-17 | Lawrence Otto Klein | Chief Executive Officer | Sell (S) | −1,729 | $41.30 | -$71.4K | EDGAR |
| 2026-03-17 | Paul T Quinlan | General Counsel | Sell (S) | −733 | $41.30 | -$30.3K | EDGAR |
| 2026-03-17 | Laura Lee Sandler | Chief Operating Officer | Sell (S) | −600 | $41.30 | -$24.8K | EDGAR |
| 2026-03-17 | Arjun Agarwal | Senior Vice President, Finance | Sell (S) | −395 | $41.30 | -$16.3K | EDGAR |
| 2026-03-17 | Joana Goncalves | Chief Medical Officer | Mixed | −641 | $24.85 | -$261.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
10 insiders · @ $69.89
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | VHCP Management EG, LLC | 10%+ Owner | 4,044,684 | $282.68M | $9.85M | 1 | 2025-02-27 |
| 2 | Tomas Kiselak | Director | 2,573,308 | $179.85M | $0 | 1 | 2025-09-19 |
| 3 | Lawrence Otto Klein | Chief Executive Officer | 927,309 | $64.81M | -$71.4K | 3 | 2026-03-17 |
| 4 | Peter Evan Harwin | Director | 798,614 | $55.82M | $0 | 1 | 2024-11-21 |
| 5 | Fairmount Healthcare Fund II L.P. | Director | 638,614 | $44.63M | $0 | 2 | 2026-06-03 |
| 6 | Laura Lee Sandler | Chief Operating Officer | 237,084 | $16.57M | -$882.8K | 6 | 2026-05-01 |
| 7 | Carl Dambkowski | Director | 86,978 | $6.08M | -$6.19M | 4 | 2026-06-03 |
| 8 | Joana Goncalves | Chief Medical Officer | 33,377 | $2.33M | -$1.87M | 8 | 2026-05-15 |
| 9 | Paul T Quinlan | General Counsel | 31,767 | $2.22M | -$30.3K | 3 | 2026-03-17 |
| 10 | Arjun Agarwal | Senior Vice President, Finance | 16,406 | $1.15M | -$624.1K | 4 | 2026-05-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 8.5 |
| EV/EBITDA | -30.6 |
| TTM Net Income | $-0.1B |
| TTM EPS | $-1.94 |
| ROE | -20.5% |